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ABSTRACT (Maximum 200 words)
Tremendous progress has been made over the past year in the development of cetaceanspecific reagents to investigate immune function in Navy marine mammals. We have focused most of our efforts in studying and developing molecular reagents and antibodies to CD4, a cell surface recognition molecule present on T helper lymphocyte that is critical for the immune response.
Previously, we cloned cetacean CD4 from a beluga cDNA library using the polymerase chain reaction and cDNA library screening techniques.
To generate antibodies against cetacean CD4, we synthesized peptides to different regions of the molecule and expressed the CD4 protein in a bacteria expression vector, and subsequently, injected coupled peptides or the purified CD4 protein into rabbits.
Both sets of antibodies were affinity purifed, and characterized by Western blot analysis and flow cytometry.
These antibodies recognized beluga and bottlenose dolphin lymphocyte lysates by Western blot analysis, but did not recognize the native form of the CD4 protein on the cell surface by flow cytometry. Immunofluorescence on tissue sections is currently being tested with these antibodies.
In addition we have generated and purifed antibodies to a variant form c CD4 we found in beluga when cloning the full-length CD4. The significance of this potential splice variant of CD4 in the beluga is currently being investigated with tl antibodies we have generated. 14. SUBJECT TERMS We have generated molecular reagents and antibodies specifically to cetacean lymphocyte markers by utilizing techniques in molecular biology and monoclonal and polyclonal antibody production. Primarily we have focused on the cell surface molecule CD4, which is critical for generation of the immune response. CD4 was cloned from a white whale, Delphinapterus leucas, thymus cDNA library using the polymerase chain reaction and cDNA library screening. Antibodies were raised to different peptide fragments of the whale CD4 molecule, as well as to the expressed CD4 protein itself. These antibodies have been characterized by ELISA, Western blot analysis, and flow cytometry.
ACCOMPLISHMENTS (last 12 months): Most of our efforts over the past 12 months have focused on the production of antibodies to whale CD4. Antibodies to whale CD4 and the variant form of CD4 we found in whale (reported last year), were produced by synthesis of peptide fragements to the whale CD4 molecule, and also expression of whale CD4 protein in a bacterial expression system. The resultant peptides were coupled to keyhole limpet hemocyanin, and injected into rabbits, while the expressed proteins were purified and injected into rabbits for antibody production. Each antibody was purifed over a protein G column and subsequently passed over an affini-ty column prepared for each individual peptide. The antibodies were tested by immunofluorescence on whale tissue sections, flow cytometry on whale peripheral blood lymphocytes, and Western blot on whale lymphocyte lysates. The antibodies work by Western blot, recognizing an approximate 65 kilodalton protein in beluga lymphocyte lysates and an approximate 60 kilodalton protein in bottlenose dolphin lymphocyte lysates. However, none of the antibodies recognized the native CD4 protein on the cell surface by flow cytometry. Expressed protein antibodies are currently being tested by immunofluorescence.
SIGNIFICANCE: The study of CD4 in cetaceans is valuable for clinical monitoring and health assessement of cetaceans kept under the Navy's care as well as for those in the wild. The CD4 reagents we presently have as well as an antibody that will recognize the native protein, (which we are currently working on), will enable us to quantify baseline levels of CD4 in Navy dolphins and whales and provide information as to how these levels change during sickness, transport, and routine and novel exercises. We will also be able to label CD4-positive lymphocytes in the lymphoid organs of hunted, stranded, and/or expired animals, and determine lymphocyte targets of postganglionic nerve fibers of the autonomic nervous system in primary and secondary lymphoid organs.
The study and comparison of whale CD4 is significant in itself given the importance of this molecule in the immune response, its interaction with major histocompatibility class II molecules, and since it is the receptor for the human immunodeficiency virus. Comparison of whale CD4 with other species has revealed interesting comparative information in regards to the evolution and adapation of the mammalian immune system (reported in the recently submitted manuscript entitled: "Molecular cloning and characterization of CD4 in an aquatic mammal, the white whale, Delphinapterus leucas", by Romano et al.) .
WORK PLAN (Next 12 months): The major objective of the next 12 months work is to produce a monoclonal antibody that recognizes the native CD4 protein.
The antibodies we have for use in Western blots will be important for health assessement of Navy cetaceans; however, it will be important to actually be able to visually see which cells in the blood and tissues are CD4 positive. In order to try to obtain an antibody against the native CD4 protein, we will clone cetacean CD4 into a mammalian expression vector, transfect into a mouse cell line, and inject CD4 expressing cells into mice for monoclonal antibody production.
In addition, we will finish characterization of the CD4 antibodies we have by working out optimal conditions for immunofluorescence on tissue sections. Further investigation will also continue on the variant form of CD4. The antibodies we have will be tested on lymphocytes maintained in culture and their supernatant, as well as whale and dolphin serum. Northern blot analysis will be carried out on various regions of the whale brain-as well, since a variant form of CD4 has been found in the mouse and human brain. 
